Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma (Q48333773)

10 February 2018

title

Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma (English)

1 reference

10 February 2018

1 reference

1 reference

C A Kruse

1

1 reference

10 February 2018

D H Mitchell

2

1 reference

10 February 2018

B K Kleinschmidt-DeMasters

3

1 reference

10 February 2018

D Bellgrau

4

1 reference

10 February 2018

J M Eule

5

1 reference

10 February 2018

J R Parra

6

1 reference

10 February 2018

Q Kong

7

1 reference

10 February 2018

K O Lillehei

8

1 reference

10 February 2018

publication date

1 February 1993

1 reference

10 February 2018

Journal of Neuro-Oncology

published in

1 reference

10 February 2018

volume

15

1 reference

10 February 2018

issue

2

1 reference

10 February 2018

page(s)

97-112

1 reference

10 February 2018

Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01053931

Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01053931

Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide

21 January 2018

1 reference

12 December 2020

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

1 reference

12 December 2020

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

12 December 2020

Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors

1 reference

12 December 2020

Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions

1 reference

12 December 2020

Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells

1 reference

12 December 2020

Immunotherapy for recurrent malignant glioma: an interim report on survival

1 reference

12 December 2020

Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro

1 reference

12 December 2020

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

12 December 2020

Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type

1 reference

12 December 2020

Cytotoxic T-cell precursors with low-level CD8 in the diabetes-prone Biobreeding rat: implications for generation of an autoimmune T-cell repertoire

1 reference

12 December 2020

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

1 reference

12 December 2020

In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells

1 reference

12 December 2020

Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.

1 reference

12 December 2020

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells

1 reference

12 December 2020

Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2

1 reference

12 December 2020

Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report

1 reference

12 December 2020

Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas.

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide

1 reference

12 December 2020

Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.

1 reference

12 December 2020

Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take

1 reference

12 December 2020

Purification and partial sequence analysis of human T-cell growth factor

1 reference

12 December 2020

Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors

1 reference

12 December 2020

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1 reference

12 December 2020

Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review

1 reference

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

12 December 2020

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

12 December 2020

Mitogen-activated lymphocytes of normals and glioma patients produce factors with anti-glioblastoma activity in vitro.

1 reference

12 December 2020

Preliminary trial of specific targeting therapy against malignant glioma

1 reference

12 December 2020

Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome

1 reference

12 December 2020

Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans

1 reference

12 December 2020

Eradication of palpable intradermal murine bladder tumors by systemic interleukin-2 and cyclophosphamide in C3H mice

1 reference

12 December 2020

Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset

1 reference

12 December 2020

Combining chemotherapy with biological response modifiers in treatment of cancer

1 reference

12 December 2020

Subsets of rat CD4+ T cells defined by their differential expression of variants of the CD45 antigen: developmental relationships and in vitro and in vivo functions

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Effects of chemotherapeutic agents on the immune response. I

1 reference

12 December 2020

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

12 December 2020

Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.

1 reference

12 December 2020

Lymphokine-activated killer cells with interleukin-2: dose toxicity and localization in isolated perfused rat lungs.

1 reference

12 December 2020

Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.

1 reference

12 December 2020

Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2

1 reference

12 December 2020

Sterile abscesses in glioma patients treated by intraparenchymal injection of lymphokine-activated killer cells and recombinant interleukin-2: case reports

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01053931

1 reference

10 February 2018

1 reference

10 February 2018